Subscribe to RSS
DOI: 10.1055/s-0038-1657360
On the Interaction Between Human Plasma Kallikrein and C1-Esterase Inhibitor
Publication History
Received 02 February 1983
Accepted 23 March 1983
Publication Date:
18 July 2018 (online)
Summary
The kinetics of the reaction between human plasma kallikrein and CĪ-esterase inhibitor was studied in a purified system. By monitoring the inhibition reaction for extended periods of time, it was found to proceed in two consecutive steps, a fast reversible second-order binding step followed by a slower, irreversible first-order transition. The rate constants in this reaction model were determined, as well as the dissociation constant of the initial, reversible enzyme-inhibitor complex. Thus, at 37° C the second-order rate constant was found to be 5 · 104 M -1 · s-1, the first order rate constant was 5 · 10-4 s-1 and the dissociation constant K was 1.5 · 10-8 M. Heparin (28 U/ml) and 6-aminohexanoic acid (10 mM) had no effect on the k1 of the of the reaction.
-
References
- 1 Haupt H, Heimburger N, Kranz T, Schwick HG. Ein Beitrag zur Isolierung und Charakterisierung des CĪ-Inaktivators aus Humanplasma. Eur J Biochem 1970; 17: 254-261
- 2 Wiman B, Nilsson T. A new simple method for determination of CĪ-esterase inhibitor activity in plasma. Clin Chim Acta 1983; 128: 359-366
- 3 Harpel PC. CĪ-Inactivator. Methods Enzymol 1976; 45: 751-760
- 4 Schapira M, Scott CF, Colman RW. Protection of human plasma kallikrein from inactivation by CĪ-inhibitor and other proteases. The role of high molecular weight kininogen. Biochemistry 1981; 20: 2738-2743
- 5 Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982; 69: 462-468
- 6 Nilsson T, Wiman B. Kinetics of the reaction between human CĪ-esterase inhibitor and CĪr or CĪs. Eur J Biochem 1983; 129: 663-667
- 7 Nilsson T, Wiman B. Purification and characterization of human CĪ-esterase inhibitor. Biochim Biophys Acta 1982; 705: 271-276
- 8 Gallimore MJ, Fareid E, Stormorken H. The purification of a human plasma kallikrein with weak plasminogen activator activity. Thromb Res 1978; 12: 409-420
- 9 Friberger P. Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. Scand J Clin Lab Invest 1982. 42. suppl 162
- 10 Kitz R, Wilson IB. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 1962; 237: 3245-3249
- 11 Nilsson T, Sjöholm I, Wiman B. Circular dichroism studies on α2-antiplasmin and its interactions with plasmin and plasminogen. Biochim Biophys Acta 1982; 705: 264-270
- 12 Rånby M, Bergsdorf N, Nilsson T. Enzymatic properties of the onechain and two-chain forms of tissue plasminogen activator. Thromb Res 1982; 27: 175-184
- 13 Beatty K, Travis J, Bieth J. The effect of α2-macroglobulin on the interaction of α1-proteinase inhibitor with porcine trypsin. Biochim Biophys Acta 1982; 704: 221-226
- 14 van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-158
- 15 Moskowitz RW, Schwartz HJ, Michel B, Ratnoff OD, Astrup T. Generation of kinin-like agents by chondroitin sulfate, heparin, chitin sulfate, and human articular cartilage: possible pathophysiologic implications. J Lab Clin Med 1970; 76: 790-798
- 16 van der Graaf F, Tans G, Bouma BN, Griffin JF. Isolation and functional properties of the heavy and light chains of human plasma kallikrein. J Biol Chem 1982; 257: 14300-14305